The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Jill Gilbert
No relevant relationships to disclose
Michael J. Schell
No relevant relationships to disclose
Xiuhua Zhao
No relevant relationships to disclose
Barbara A. Murphy
No relevant relationships to disclose
Tawee Tanvetyanon
No relevant relationships to disclose
David N. Hayes
No relevant relationships to disclose
Missak Haigentz
Stock Ownership - Lilly
Nabil F. Saba
No relevant relationships to disclose
Jorge J. Nieva
No relevant relationships to disclose
Jimena Perez
No relevant relationships to disclose
Justin A. Bishop
No relevant relationships to disclose
Christine H. Chung
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bayer